Simulation von Aortenerkrankungen für die Therapieplanung basierend auf 4D MRT- und Phasenkontrastbildgebung

Sebastian Schalck,T. Müller,Roland Unterhinninghofen,H. Tengg-Kobligk,H. Kauczor,R. Dillmann

Abstract:

What problem does this paper attempt to address?

[The 4 serum bilirubin fractions in obstructive jaundice].

M. Sommerhalder,C. Kuenzle,J. Ruettner,C. Maier

1962-12-01

Abstract:
AMCP Partnership Forum: Improving Quality, Value, and Outcomes with Patient-Reported Outcomes

DOI: https://doi.org/10.18553/jmcp.2018.17491

Abstract:Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing value-based payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patient-centered care. Disclosures: The AMCP Partnership Forum titled "Improving Quality, Value, and Outcomes with Patient-Reported Outcomes" and the development of this proceedings report were supported by Amgen, Boehringer Ingelheim Pharmaceuticals, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals, Novo Nordisk, Precision for Value, Premier, Sanofi, Takeda Pharmaceuticals USA, and Xcenda.
AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement

DOI: https://doi.org/10.18553/jmcp.2020.20121

Abstract:Rising specialty drug costs present a challenge for patients and payers. High-cost products, such as gene therapies or immunotherapies, can significantly affect the budget of a payer that does not have the ability to spread risk across a large population. Stakeholders are considering new reimbursement and benefit designs for specialty medications to improve efficiencies and better manage costs. The potential effect of changes to specialty medication benefit designs and reimbursement systems on patient care, access to medications, and the overall health care system are important considerations when assessing the benefits and challenges associated with reform proposals. Options to better manage the affordability of specialty medications are needed to ensure that patients can continue to access medications, while allowing payers to remain good stewards of health care dollars and supporting marketplace competition and incentives to stimulate innovation. New benefit designs that address these needs, while also supporting marketplace competition and providing incentives that stimulate innovation, have been considered. To explore options, AMCP convened a multidisciplinary stakeholder forum on December 10-11, 2019, in Alexandria, VA. Health care leaders representing academia, health plans, integrated delivery systems, industry leaders, pharmaceutical manufacturers, pharmacy benefit managers, employers, federal government agencies, national health care provider organizations, and patient advocacy organizations participated in the forum. The forum was designed for stakeholders to discuss strategies for the following: (a) reduce costs for beneficiaries while maintaining or improving access to prescription drugs; (b) support marketplace competition and incentives for biopharmaceutical innovation; (c) minimize physicians' financial risk associated with managing drug inventories; (d) remove adverse reimbursement incentives for prescribing higher priced drugs; (e) consider the cost-effectiveness of treatments and services across the health care continuum; and (f) support quality measurement and program evaluation metrics. Recommendations emerging from the forum included creation of novel payment models for the most expensive therapies that allow for larger risk pools, while maintaining the sustainability of the reinsurance market remains. Simplification and standardization were cited as goals for system reform and technological innovations that allow health care providers to view cost-effectiveness information at the point of prescribing, combined with value-based contracting were also recommended. Finally, ensuring that plans remain patient-centric and are designed to address patient needs holistically was stressed as an important goal. DISCLOSURES: This partnership forum was sponsored by Amgen, AstraZeneca, Bayer, GSK, Merck, Pfizer, PhRMA, Takeda, and Xcenda. These proceedings were prepared as a summary of the forum to represent common themes; they are not necessarily endorsed by all attendees nor should they be construed as reflecting group consensus.
AMCP Partnership Forum: Biosimilars-policy, practice, and postmarketing surveillance to support treatment and coverage decisions

DOI: https://doi.org/10.18553/jmcp.2021.21103

Abstract:With the dual goals of identifying key actions that can support the further development and use of biosimilars in the United States and providing consistent and accurate messages about the value of biosimilars, AMCP held a virtual multidisciplinary stakeholder forum December 15-16, 2020. The participants, including payers, pharmacists, integrated delivery system leaders, health economists and analysts, academicians, patient advocates, pharmaceutical manufacturers, and other key decision makers, spent the 2 days (1) identifying challenges with biosimilar adoption within the US health care system; (2) determining clear and unbiased scientific messaging to support broader acceptance of biologics as valid therapeutic options and to facilitate faster time to biosimilar adoption; and (3) discussing needs and opportunities related to real-world evidence to help with adoption of biosimilars. Participants identified various challenges, including approval-related nuances and other regulatory considerations; general information about biosimilars and lack of consistent, positive messaging; clinical and administrative barriers; and economic complexities and variation. They also highlighted areas of opportunity, such as demystifying information and developing strong, positive messaging around biologics and biosimilars, and improving confidence in biosimilars by using tools such as education and real-world evidence, organizational strategies to ease biosimilar adoption, and updates to legislation and regulation to reduce barriers related to biosimilars. DISCLOSURES: This forum was sponsored by Amgen, the Association for Accessible Medicines, Boehringer Ingelheim, Fresenius Kabi, Johnson & Johnson, Novo Nordisk, Pfizer, Sandoz, and Takeda. These proceedings were prepared as a summary of the forum to represent common themes; they are not necessarily endorsed by all attendees, nor should they be construed as reflecting group consensus.
Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities

Jacques S. Beckmann,Daniel Lew

DOI: https://doi.org/10.1186/s13073-016-0388-7

IF: 15.266

2016-12-01

Genome Medicine

Abstract:This era of groundbreaking scientific developments in high-resolution, high-throughput technologies is allowing the cost-effective collection and analysis of huge, disparate datasets on individual health. Proper data mining and translation of the vast datasets into clinically actionable knowledge will require the application of clinical bioinformatics. These developments have triggered multiple national initiatives in precision medicine—a data-driven approach centering on the individual. However, clinical implementation of precision medicine poses numerous challenges. Foremost, precision medicine needs to be contrasted with the powerful and widely used practice of evidence-based medicine, which is informed by meta-analyses or group-centered studies from which mean recommendations are derived. This “one size fits all” approach can provide inadequate solutions for outliers. Such outliers, which are far from an oddity as all of us fall into this category for some traits, can be better managed using precision medicine. Here, we argue that it is necessary and possible to bridge between precision medicine and evidence-based medicine. This will require worldwide and responsible data sharing, as well as regularly updated training programs. We also discuss the challenges and opportunities for achieving clinical utility in precision medicine. We project that, through collection, analyses and sharing of standardized medically relevant data globally, evidence-based precision medicine will shift progressively from therapy to prevention, thus leading eventually to improved, clinician-to-patient communication, citizen-centered healthcare and sustained well-being.

genetics & heredity
Precision Medicine: From Science To Value

Geoffrey S Ginsburg,Kathryn A Phillips,Geoffrey S. Ginsburg,Kathryn A. Phillips

DOI: https://doi.org/10.1377/hlthaff.2017.1624

2018-05-01

Health Affairs

Abstract:Precision medicine is making an impact on patients, health care delivery systems, and research participants in ways that were only imagined fifteen years ago when the human genome was first sequenced. Discovery of disease-causing and drug-response genetic variants has accelerated, while adoption into clinical medicine has lagged. We define precision medicine and the stakeholder community required to enable its integration into research and health care. We explore the intersection of data science, analytics, and precision medicine in the formation of health systems that carry out research in the context of clinical care and that optimize the tools and information used to deliver improved patient outcomes. We provide examples of real-world impact and conclude with a policy and economic agenda necessary for the adoption of this new paradigm of health care both in the United States and globally.

health care sciences & services,health policy & services
AMCP Partnership Forum: Advancing Value-Based Contracting

DOI: https://doi.org/10.18553/jmcp.2017.17342

Abstract:During the past decade, payment models for the delivery of health care have undergone a dramatic shift from focusing on volume to focusing on value. This shift began with the Affordable Care Act and was reinforced by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), which increased the emphasis on payment for delivery of quality care. Today, value-based care is a primary strategy for improving patient care while managing costs. This shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers. Value-based contracts (VBCs) have emerged as a mechanism that payers may use to better align their contracting structures with broader changes in the health care system. While pharmaceuticals represent a small share of total health care spending, it is one of the fastest-growing segments of the health care marketplace, and the increasing costs of pharmaceuticals necessitate more flexibility to contract in new ways based on the value of these products. Although not all products or services are appropriate for these types of contracts, VBCs could be a part of the solution to address increasing drug prices and overall drug spending. VBCs encompass a variety of different contracting strategies for biopharmaceutical products that do not base payment rates on volume. These contracts instead may include payment on the achievement of specific goals in a predetermined patient population and offer innovative solutions for quantifying and rewarding positive outcomes or otherwise reducing payer risk associated with pharmaceutical costs. To engage national stakeholders in a discussion of current practices, barriers, and potential benefits of VBCs, the Academy of Managed Care Pharmacy (AMCP) convened a Partnership Forum on Advancing Value-Based Contracting in Arlington, Virginia, on June 20-21, 2017. The goals of the VBC forum were as follows: (a) agree to a definition of a VBC for facilitating discussion with key policy makers and regulators; (b) determine strategies for advancing the development and utilization of performance benchmarks; (c) identify best practices in evaluating, implementing, and monitoring VBCs; and (d) develop action plans to mitigate legal and regulatory barriers to VBCs. More than 30 national and regional health care leaders representing health plans, integrated delivery systems, pharmacy benefit managers, employers, data and analytics companies, and biopharmaceutical companies participated. Speakers, panelists, and stakeholders attended the forum and explored the current environment for VBCs, identified challenges to the expansion of VBCs, offered potential solutions to those challenges, and developed an action plan for addressing selected challenges. The forum recommendations will be used by AMCP to establish a coalition of organizations to seek broader acceptance of VBCs in the marketplace and by policymakers. The recommendations will also help AMCP provide tools and resources to stakeholders in managing VBCs. Disclosures: This Partnership Forum was supported by Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, the National Pharmaceutical Council, Novo Nordisk, Premier, the Pharmaceutical Research and Manufacturers of America, RxAnte, Takeda, and Xcenda.
STRIPE partners in precision medicine series: provider perspective

Christine M. Formea,Paldeep Atwal,Kathryn Meintsma,Martin Dawes,Gary Marchant,Ben L. Kong,J. Shawn Jones,Sara L. Rogers

DOI: https://doi.org/10.1038/s41397-024-00348-9

2024-08-25

The Pharmacogenomics Journal

Abstract:During the "Provider Perspective" session, Dr. Paldeep Atwal, Kathryn Meintsma, Dr. Martin Dawes, and Dr. Gary Marchant provided their perspectives for health care providers who are considering the incorporation of science and technology into their clinical setting during a discussion moderated by Dr. Christine Formea. Speakers discussed areas of ongoing debate including genomics malpractice, clinical use, clinical decision support, and compliance. Dr. Paldeep Atwal MD, MBA, Physician and Director of Atwal Clinic for Genomic and Personalized Medicine and Medical Director for Genetic Services at Everly Health Solutions, shared a concierge clinic perspective. He discussed direct-to-consumer testing versus consumer-initiated testing approaches for pharmacogenomics. Direct-to-consumer testing does not require the involvement of a health care provider while consumer-initiated testing requires an order from a health care provider and is handled by the clinical care team. Consumer-initiated testing can be more beneficial for clinical decision making due to clinical oversight and CLIA-certified clinical laboratory testing. Pharmacogenomics barriers exist due to lack of awareness of its benefits. When patients initiate their own pharmacogenomics testing, barriers can be reduced to increase access. Additionally, Dr. Atwal recommended that health care providers seek the specialized expertise of pharmacogenomics-trained pharmacists as they begin incorporating these skills into their clinical practice. As non-genetics trained health care providers begin using this information, it is important to remember to use pharmacogenomics in conjunction with other medication information including drug-drug interactions and phenoconversion (i.e., a mismatch between a person's genotype-predicted drug metabolism and their actual or observed phenotypic drug metabolism due to non-genetic factors such as drug inducers or inhibitors) to create actionable medical plans that can be shared with patients and other health care providers for more effective clinical care. He encouraged using genomics resources such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) website for additional information.

pharmacology & pharmacy,genetics & heredity
Frontiers in Precision Medicine: Exploring Science and Policy Boundaries

Jorge L. Contreras,Leslie P. Francis

DOI: https://doi.org/10.2139/ssrn.2851946

2016-01-01

SSRN Electronic Journal

Abstract:Precision medicine is being developed today within a complex landscape of public policy, science, economics, law, and regulation. Important features of this landscape include health care financing, patent protection for new innovations, regulatory approvals of tests and therapies, patient consent and access, and protection of privacy. In these and other policy areas, the goal of developing individually-tailored therapies poses novel challenges for health care research, delivery and policy. In December 2015, the University of Utah School of Medicine, Huntsman Cancer Institute and S.J. Quinney College of Law convened a two-day symposium at which national experts in genetics, medicine, bioinformatics, intellectual property, regulatory science, health economics and bioethics discussed and debated many of the pressing questions raised by precision medicine. The key arguments, conclusions and unresolved issues that emerged from the symposium are summarized in these proceedings.
Precision Medicine Approaches in Oncology: Current Trends and Future Directions

Andi Asrina

DOI: https://doi.org/10.60079/ahr.v2i1.370

2024-02-28

Abstract:Purpose: This study explores the transformative potential of precision medicine in oncology, highlighting advancements in targeted therapies and immunotherapies and addressing practical and theoretical challenges in clinical implementation. Research Design and Methodology: Utilizing a mixed-methods design, the study integrates quantitative data from a cross-sectional survey of oncologists and qualitative insights from in-depth interviews with key stakeholders. Advanced bioinformatics tools and multi-omics data (genomics, proteomics, and transcriptomics) are analyzed to identify novel therapeutic targets and biomarkers. Findings and Discussion: The findings show that precision medicine improves patient outcomes by tailoring treatments to tumors' genetic and molecular profiles. Targeted therapies, such as tyrosine kinase and epidermal growth factor receptor inhibitors, exhibit enhanced efficacy and reduced toxicity. Immunotherapy, remarkably immune checkpoint inhibitors, demonstrates significant promise but shows variability in patient responses, underscoring the need for predictive biomarkers. Integrating multi-omics data provides a comprehensive understanding of cancer biology and new therapeutic targets. Challenges include high costs, the need for robust bioinformatics infrastructure, and ethical considerations. Implications: This study underscores the need for investment in bioinformatics infrastructure, standardized guidelines, and training for healthcare providers. Policymakers should develop strategies to lower genetic testing costs and ensure equitable access to precision medicine. Future research should focus on cost-effective genomic testing methods, combination therapies to overcome resistance, and expanding studies to diverse populations to enhance the applicability and accessibility of precision medicine benefits.

Medicine,Biology
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm

Nesrine Lajmi,Sofia Alves-Vasconcelos,Apostolos Tsiachristas,Andrew Haworth,Kerrie Woods,Charles Crichton,Theresa Noble,Hizni Salih,Kinga A Várnai,Harriet Branford-White,Liam Orrell,Andrew Osman,Kevin M Bradley,Lara Bonney,Daniel R McGowan,Jim Davies,Matthew S Prime,Andrew Bassim Hassan

DOI: https://doi.org/10.1017/pcm.2024.1

2024-03-26

Abstract:The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.
Academic medical centers as innovation ecosystems to address population –omics challenges in precision medicine

Patrick J. Silva,Valerie M. Schaibley,Kenneth S. Ramos

DOI: https://doi.org/10.1186/s12967-018-1401-2

IF: 8.44

2018-02-15

Journal of Translational Medicine

Abstract:While the promise of the Human Genome Project provided significant insights into the structure of the human genome, the complexities of disease at the individual level have made it difficult to utilize –omic information in clinical decision making. Some of the existing constraints have been minimized by technological advancements that have reduced the cost of sequencing to a rate far in excess of Moore’s Law (a halving in cost per unit output every 18 months). The reduction in sequencing costs has made it economically feasible to create large data commons capturing the diversity of disease across populations. Until recently, these data have primarily been consumed in clinical research, but now increasingly being considered in clinical decision- making. Such advances are disrupting common diagnostic business models around which academic medical centers (AMCs) and molecular diagnostic companies have collaborated over the last decade. Proprietary biomarkers and patents on proprietary diagnostic content are no longer driving biomarker collaborations between industry and AMCs. Increasingly the scope of the data commons and biorepositories that AMCs can assemble through a nexus of academic and pharma collaborations is driving a virtuous cycle of precision medicine capabilities that make an AMC relevant and highly competitive. A rebalancing of proprietary strategies and open innovation strategies is warranted to enable institutional precision medicine asset portfolios. The scope of the AMC’s clinical trial and research collaboration portfolios with industry are increasingly dependent on the currency of data, and less on patents. Intrapeneurial support of internal service offerings, clinical trials and clinical laboratory services for example, will be important new points of emphasis at the academic-industry interface. Streamlining these new models of industry collaboration for AMCs are a new area for technology transfer offices to offer partnerships and to add value beyond the traditional intellectual property offering.

medicine, research & experimental
Problems, challenges and promises: perspectives on precision medicine

David J Duffy,David J. Duffy

DOI: https://doi.org/10.1093/bib/bbv060

IF: 9.5

2015-08-05

Briefings in Bioinformatics

Abstract:The 'precision medicine (systems medicine)' concept promises to achieve a shift to future healthcare systems with a more proactive and predictive approach to medicine, where the emphasis is on disease prevention rather than the treatment of symptoms. The individualization of treatment for each patient will be at the centre of this approach, with all of a patient's medical data being computationally integrated and accessible. Precision medicine is being rapidly embraced by biomedical researchers, pioneering clinicians and scientific funding programmes in both the European Union (EU) and USA. Precision medicine is a key component of both Horizon 2020 (the EU Framework Programme for Research and Innovation) and the White House's Precision Medicine Initiative. Precision medicine promises to revolutionize patient care and treatment decisions. However, the participants in precision medicine are faced with a considerable central challenge. Greater volumes of data from a wider variety of sources are being generated and analysed than ever before; yet, this heterogeneous information must be integrated and incorporated into personalized predictive models, the output of which must be intelligible to non-computationally trained clinicians. Drawing primarily from the field of 'oncology', this article will introduce key concepts and challenges of precision medicine and some of the approaches currently being implemented to overcome these challenges. Finally, this article also covers the criticisms of precision medicine overpromising on its potential to transform patient care.

biochemical research methods,mathematical & computational biology
Precision reimbursement for precision medicine: the need for patient-level decisions between payers, providers and pharmaceutical companies

Sanjay Budhdeo,Michael Ruhl,Paul M Agapow,Nikhil Sharma,Parker Moss

DOI: https://doi.org/10.7861/fhj.2021-0066

2021-09-23

Future Healthcare Journal

Abstract:Healthcare costs have been dramatically rising in developed economies worldwide. A key driver of cost increases has been high-cost drugs. The current model of reimbursement is not configured for drugs with uncertain outcomes. Future reimbursement will require better allocation of available healthcare system funds. Technological advancements have opened the door to a new type of outcomes-based reimbursement, enabling value exchange between payers and pharmaceutical companies, which we term precision reimbursement. Precision reimbursement extends beyond value-based contracts, with decisions at individual rather than aggregate level. For precision reimbursement to be adopted, there are data, computation and infrastructure requirements. All stakeholders benefit in moving to precision reimbursement for optimal resource allocation, risk sharing and, ultimately, improved outcomes. There are implementation challenges including cost, change management, information governance and development of surrogate markers. The overarching trend in medicine is toward personalised interventions, with precision reimbursement as the logical consequence.
Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.

Edward S. Kim,Jennifer L. Ersek,M. Thompson,L. Black

DOI: https://doi.org/10.1200/EDBK_200633

2018-05-23

Abstract:There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with cancer are treated. However, community-based practices, as well as some academic centers, may face unique barriers to implementing precision medicine programs and trials within their communities. Such challenges include understanding the tissue needs of molecular tests (e.g., tumor, blood), identifying which molecular tests are best used and when tissue should be tested, interpreting the test results and determining actionability, understanding the role of genetic counseling and/or follow-up testing, determining clinical trial eligibility, and assessing patient attitudes and financial concerns. The purpose of this article is to provide guidance to community-based oncology practices currently conducting clinical trials who want to expand their research program to include precision medicine trials. Here, we describe the core components of precision medicine programs and offer best practices for successful implementation of precision medicine trials in community-based practices.

Medicine
Optimizing Clinical Workflow Using Precision Medicine and Advanced Data Analytics

Kevin Zhai,Mohammad S. Yousef,Sawsan Mohammed,Nader I. Al-Dewik,M. Walid Qoronfleh

DOI: https://doi.org/10.3390/pr11030939

IF: 3.5

2023-03-20

Processes

Abstract:Precision medicine—of which precision prescribing is a core component—is becoming a new frontier in today's healthcare. Both artificial intelligence (AI) and machine learning (ML) have the potential to enhance our understanding of data and therefore our ability to accurately diagnose and treat patients. By leveraging these technologies and processes, we can uncover associations between a person's genomic makeup and their health, identify biomarkers associated with diseases, fine-tune patient selection for clinical trials, reduce costs, and accelerate drug discovery and vaccine development. Although real-world data pose challenges in terms of collection, representation, and missing or inaccurate data sets, the integration of precision medicine into healthcare is critical. Clearly, precision medicine can benefit from health information innovations that empower decision-making at the patient level. Healthcare fusion is an example of an innovative framework and process [K Zhai et al., 2022, pp. 179–192] [K Zhai et al. ECKM 2022, 20(3), pp. 179–192]. Data science and process improvement are also expected to play a role in resource planning and operational efficiency for optimal patient-centered care. Driving this transformation are advances in 'omics' technologies, digital devices, and imaging capabilities, along with an arsenal of powerful analytics tools working across a multitude of institutions and stakeholders. Encompassing this entire ecosystem, medicine will be evidence-based and driven by three key components: (1) Data curation through clinical diagnostics and behavioral apps that capture health and disease states; (2) Individualized solutions driven by advanced data analytics and personalized therapies; and (3) Business models that deliver value and incentivize growth. The aim of this paper is to present a novel conceptual framework to leverage AI and enhance information flow to serve the patient as per components one and two.

engineering, chemical
Precision Medicine: Steps along the Road to Combat Human Cancer

Samuel F. Nassar,Khadir Raddassi,Baljit Ubhi,Joseph Doktorski,Ahmad Abulaban

DOI: https://doi.org/10.3390/cells9092056

IF: 6

2020-09-09

Cells

Abstract:The diagnosis and treatment of diseases such as cancer is becoming more accurate and specialized with the advent of precision medicine techniques, research and treatments. Reaching down to the cellular and even sub-cellular level, diagnostic tests can pinpoint specific, individual information from each patient, and guide providers to a more accurate plan of treatment. With this advanced knowledge, researchers and providers can better gauge the effectiveness of drugs, radiation, and other therapies, which is bound to lead to a more accurate, if not more positive, prognosis. As precision medicine becomes more established, new techniques, equipment, materials and testing methods will be required. Herein, we will examine the recent innovations in assays, devices and software, along with next generation sequencing in genomics diagnostics which are in use or are being developed for personalized medicine. So as to avoid duplication and produce the fullest possible benefit, all involved must be strongly encouraged to collaborate, across national borders, public and private sectors, science, medicine and academia alike. In this paper we will offer recommendations for tools, research and development, along with ideas for implementation. We plan to begin with discussion of the lessons learned to date, and the current research on pharmacogenomics. Given the steady stream of advances in imaging mass spectrometry and nanoLC-MS/MS, and use of genomic, proteomic and metabolomics biomarkers to distinguish healthy tissue from diseased cells, there is great potential to utilize pharmacogenomics to tailor a drug or drugs to a particular cohort of patients. Such efforts very well may bring increased hope for small groups of non-responders and those who have demonstrated adverse reactions to current treatments.

cell biology
Artificial Intelligence, Healthcare, Clinical Genomics, and Pharmacogenomics Approaches in Precision Medicine

Habiba Abdelhalim,Asude Berber,Mudassir Lodi,Rihi Jain,Achuth Nair,Anirudh Pappu,Kush Patel,Vignesh Venkat,Cynthia Venkatesan,Raghu Wable,Matthew Dinatale,Allyson Fu,Vikram Iyer,Ishan Kalove,Marc Kleyman,Joseph Koutsoutis,David Menna,Mayank Paliwal,Nishi Patel,Thirth Patel,Zara Rafique,Rothela Samadi,Roshan Varadhan,Shreyas Bolla,Sreya Vadapalli,Zeeshan Ahmed

DOI: https://doi.org/10.3389/fgene.2022.929736

IF: 3.7

2022-07-07

Frontiers in Genetics

Abstract:Precision medicine has greatly aided in improving health outcomes using earlier diagnosis and better prognosis for chronic diseases. It makes use of clinical data associated with the patient as well as their multi-omics/genomic data to reach a conclusion regarding how a physician should proceed with a specific treatment. Compared to the symptom-driven approach in medicine, precision medicine considers the critical fact that all patients do not react to the same treatment or medication in the same way. When considering the intersection of traditionally distinct arenas of medicine, that is, artificial intelligence, healthcare, clinical genomics, and pharmacogenomics—what ties them together is their impact on the development of precision medicine as a field and how they each contribute to patient-specific, rather than symptom-specific patient outcomes. This study discusses the impact and integration of these different fields in the scope of precision medicine and how they can be used in preventing and predicting acute or chronic diseases. Additionally, this study also discusses the advantages as well as the current challenges associated with artificial intelligence, healthcare, clinical genomics, and pharmacogenomics.

genetics & heredity
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens

Priscila Radu,Gayathri Kumar,Amanda Cole,Aikaterini Fameli,Mark Guthrie,Lieven Annemans,Jan Geissler,Antoine Italiano,Brian O’Rourke,Entela Xoxi,Lotte Steuten

DOI: https://doi.org/10.1093/oncolo/oyae060

2024-04-17

The Oncologist

Abstract:Abstract Background Genomic and molecular alterations are increasingly important in cancer diagnosis, and scientific advances are opening new treatment avenues. Precision oncology (PO) uses a patient’s genomic profile to determine optimal treatment, promising fewer side effects and higher success rates. Within PO, tumor-agnostic (TA) therapies target genomic alterations irrespective of tumor location. However, traditional value frameworks and approval pathways pose challenges which may limit patient access to PO therapies. Objectives This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an iterative life-cycle assessment of these medicines. Methods After reviewing the published literature, we obtained insights from key stakeholders and European experts across a range of disciplines, through individual interviews and an industry workshop. The research was guided and refined by an international expert committee through 2 sounding board meetings. Results The current challenges faced by PO and TA medicines are multiple and can be demonstrated through real-world examples of the current barriers and opportunities. A life-cycle approach to assessment should be taken, including key actions at the early stages of evidence generation, regulatory and reimbursement stage, as well as payment and adoption solutions that make use of the evolving evidence base. Working toward these solutions to maximize PO medicine value is a shared responsibility and stands to benefit all stakeholders. Conclusions Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.

oncology
Overcoming barriers to adoption of precision medicine in community oncology centers in the rural southeastern United States using novel informatics tools and academic collaborations.

Bennett Adam Caughey,Anivarya Kumar,Jennifer R. Owen,Nicholette Sloat,Elizabeth Maynard,Vanessa Hill,Christopher Hubbard,Benjamin Neely,Matthew Stuart McKinney,Linda Sutton,Shannon J. McCall,Michael Datto,John H. Strickler,Michelle Green

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e13514

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e13514 Background: Comprehensive genomic profiling (CGP) is an important tool to identify actionable biomarkers and guide cancer therapy. However, patient (pt) race, socioeconomic status, and clinical setting are associated with lower access to CGP, targeted therapies, and clinical trials. To address this, we expanded a novel framework for genomic data management and clinical decision support developed at a large academic medical center to a network of affiliated community cancer centers located in rural, traditionally underserved communities. Methods: The Duke Precision Cancer Medicine Initiative (PCMI) developed a centralized database to aggregate and normalize CGP results. This database enables CGP review by a multi-disciplinary Molecular Tumor Board (MTB). PCMI established a protocol that allows the MTB to review CGP results and relevant clinical data for consented patients. This protocol opened enrollment at four DCN-affiliated cancer centers in rural North Carolina. Clinical recommendations are captured in a standard note and returned to DCN providers following each review. Our protocol also includes an anonymous survey sent to oncology providers asking about barriers to access and utilization of CGP. Results: Between Jan 2022 and Jan 2023, 62 pts were enrolled and had CGP results reviewed by the MTB; 13 pts (21.0%) were Native American and 20 (32.3%) were Black. 61 actionable genomic alterations were identified from 38 pts, including 16 (25.6%) that molecularly matched clinical trial inclusion criteria. Most DCN providers reported being comfortable ordering (14/20) CGP though fewer expressed comfort with interpretation (9/20) CGP; provider-reported barriers included cost/insurance for targeted therapies (12/20) and distance to clinical trials (14/20). Conclusions: Successful academic-community partnerships to expand access to CGP, clinical trials, and targeted therapies are feasible when supported by fit-for-purpose informatics tools and scalable workflows. Additional work is required to develop comprehensive solutions that ensure equal access to CGP and precision medicine for all patients. [Table: see text]

oncology

Simulation von Aortenerkrankungen für die Therapieplanung basierend auf 4D MRT- und Phasenkontrastbildgebung

[The 4 serum bilirubin fractions in obstructive jaundice].

AMCP Partnership Forum: Improving Quality, Value, and Outcomes with Patient-Reported Outcomes

AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement

AMCP Partnership Forum: Biosimilars-policy, practice, and postmarketing surveillance to support treatment and coverage decisions

Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities

Precision Medicine: From Science To Value

AMCP Partnership Forum: Advancing Value-Based Contracting

STRIPE partners in precision medicine series: provider perspective

Frontiers in Precision Medicine: Exploring Science and Policy Boundaries

Precision Medicine Approaches in Oncology: Current Trends and Future Directions

Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm

Academic medical centers as innovation ecosystems to address population –omics challenges in precision medicine

Problems, challenges and promises: perspectives on precision medicine

Precision reimbursement for precision medicine: the need for patient-level decisions between payers, providers and pharmaceutical companies

Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.

Optimizing Clinical Workflow Using Precision Medicine and Advanced Data Analytics

Precision Medicine: Steps along the Road to Combat Human Cancer

Artificial Intelligence, Healthcare, Clinical Genomics, and Pharmacogenomics Approaches in Precision Medicine

Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens

Overcoming barriers to adoption of precision medicine in community oncology centers in the rural southeastern United States using novel informatics tools and academic collaborations.